{"nctId":"NCT00248170","briefTitle":"Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer","startDateStruct":{"date":"2005-12"},"conditions":["Breast Cancer"],"count":4172,"armGroups":[{"label":"Letrozole","type":"EXPERIMENTAL","interventionNames":["Drug: Letrozole"]},{"label":"Anastrozole","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Anastrozole"]}],"interventions":[{"name":"Letrozole","otherNames":[]},{"name":"Anastrozole","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Recent primary surgery for breast cancer\n* Early stage breast cancer\n* Postmenopausal\n* Hormone receptor positive\n* Positive lymph node involvement\n\nExclusion Criteria:\n\n* Metastatic disease\n* Presence of contralateral breast cancer including DCIS\n* Progression\n\nOther protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"33 Years","maximumAge":"96 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Disease Free Survival","description":"Disease-free survival was defined as the time from the date of randomization to the date of the first documentation of re-occurrence of invasive breast cancer in local, regional or distant sites, new invasive breast cancer in the contra-lateral breast, or death from any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival was defined as the time from the date of randomization to the date of death from any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Development of Distant Metastases","description":"Time to development of distant metastases was defined as the time from date of randomization to the date of the first development of any recurrent or metastatic disease in sites other than the local mastectomy scar, the ipsilateral breast in case of breast conservation or the contra lateral breast.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Development of Contra Lateral Breast Cancer","description":"Time to development of contra lateral breast cancer was defined as the time from the date of randomization to the date of the first development of any disease in the contra lateral breast.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Distant Disease-free Survival","description":"Distant disease-free survival was defined as the time from date of randomization to the date of the first development of any relapse at a distant site or death from any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum Lipid Profiles","description":"Total cholesterol was analyzed to assess the impact on serum lipids profiles. The adjusted means was calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.643","spread":null},{"groupId":"OG001","value":"5.553","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.569","spread":null},{"groupId":"OG001","value":"5.511","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.508","spread":null},{"groupId":"OG001","value":"5.436","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.429","spread":null},{"groupId":"OG001","value":"5.427","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.395","spread":null},{"groupId":"OG001","value":"5.366","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.375","spread":null},{"groupId":"OG001","value":"5.368","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Experienced Clinical Fracture Events","description":"The incidence of clinical fractures was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","spread":null},{"groupId":"OG001","value":"8.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Experienced Cardiovascular Events","description":"The incidence of ischemic heart disease, cardiac failures, cerebrovascular accidents and thromboembolic events was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"1.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":486,"n":2049},"commonTop":["Arthralgia","Hot flush","Fatigue","Osteoporosis","Myalgia"]}}}